Characterization of a human monoclonal antibody to lipopolysaccharides of Pseudomonas aeruginosa serotype 5: a possible candidate as an immunotherapeutic agent for infections with P. aeruginosa.
A human monoclonal antibody, P3D9 (IgG2, lambda type), that bound to Pseudomonas aeruginosa Homma serotype 5 cells with high specificity was produced by cell fusion between a human tonsillar lymphocyte and a mouse plasmacytoma cell, P3-X63-Ag8-U1 (P3U1). The yield of P3D9 secreted into the culture supernatant from the mouse-human hybridoma was 2-10 micrograms/ml, and this hybridoma cell line has been stably producing this antibody for six months. Antibody P3D9 alone did not cause agglutination of serotype 5 cells, but the cells were agglutinated after addition of goat antibody to human IgG. Antibody P3D9 was proven to have protective activity against infection with P. aeruginosa, and the 50% protective dose estimated for experimental peritoneal infection with P. aeruginosa was 2.4 micrograms per mouse.
D000372:Agglutination Tests; D000818:Animals; D000907:Antibodies, Bacterial / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000918:Antibody Specificity; D006801:Humans; D006825:Hybridomas; D008070:Lipopolysaccharides / Q000276:immunology*; D051379:Mice; D011552:Pseudomonas Infections / Q000628:therapy*; D011550:Pseudomonas aeruginosa / Q000145:classification / Q000276:immunology*; D012703:Serotyping
D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D008070:Lipopolysaccharides